Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Triple agonist (GLP-1 / GIP / GCG) under investigation in metabolic research
Outcomes observed in Phase 2 trials under carefully controlled conditions may differ from those seen in real-world clinical practice
Easy daily use at home or on the go
This is why many people report feeling more "sharp" and focused when they prioritize their antioxidant intake
When an amylin analogue like cagrilintide is paired with a GLP-1/GIP receptor agonist, the complementary mechanisms appear to produce additive appetite suppression: cagrilintide slows gastric emptying through amylin receptor activation, while tirzepatide simultaneously boosts insulin secretion and reduces glucagon
